
is way under. Their market cap is $109B. Divide by $500M and it’s 218. Moderna is crazy as well and I own CRSP, but I’d put those squarely in the pre-revenue bucket. They may have revenue but that’s like partnership investments that they have to record as revenue versus SNOW which already has a product being sold.
So, we have 4 pre-revenue Biotech type companies, 2 of which are tied directly to CV-19 vaccines and a database/analytics company whose P/S is 3 times more than any other software/cloud/tech company in the world. Is it overvalued, hmm, maybe.
Think about it. It’s up around 10x the original IPO price before they realized it was so oversubscribed that they could triple the price with no issue. It’s then tripled from there all based on being hot. The quarter they just reported wasn’t special, it’s what was expected two months ago when the valuation was expected to be $10B.
If there is any type of dip or if they miss revenue at any point in the next 12 months the stock should crater 50% in a day. No thanks.